Anorexia Clinical Trial
Official title:
A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia
RATIONALE: Megestrol acetate may help improve appetite and lessen weight loss caused by cancer. PURPOSE: This clinical trial studies megestrol acetate in treating weight loss or anorexia in young patients with malignancies who are undergoing radiation therapy and/or chemotherapy.
PRIMARY OBJECTIVES:Proportion of Patients Who Maintain Weight or Experience Weight Gain.
SECONDARY OBJECTIVES:BMI Trends, Caloric Intake, Weight Maintenance Over Time, Toxicity
Profile as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.
OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive oral
megestrol acetate 1-2 times (10 mg/kg dose if once daily or 5 mg/kg dose if twice daily)
daily for 4 weeks. ARM B (control): Patients are observed for weight loss and gain for 4
weeks. After completion of study treatment, patients are followed up for 12 weeks.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01501396 -
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
|
Phase 2 | |
| Withdrawn |
NCT02793102 -
Sensory Workshops and Anorexia Nervosa
|
N/A | |
| Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
| Completed |
NCT02524301 -
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
|
N/A | |
| Active, not recruiting |
NCT00488072 -
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
|
Phase 2 | |
| Withdrawn |
NCT05039385 -
Exercise Program in Patients With Anorexia Nervosa (ESATRAL)
|
N/A | |
| Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
| Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
| Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
| Completed |
NCT00040885 -
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
|
Phase 3 | |
| Completed |
NCT00006799 -
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT04007900 -
Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
|
N/A | |
| Completed |
NCT00735540 -
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
|
N/A | |
| Completed |
NCT00046904 -
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
|
Phase 3 | |
| Completed |
NCT04803305 -
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
|
Phase 1 | |
| Completed |
NCT05708404 -
Outpatient Treatment of Severe and Enduring Anorexia Nervosa
|
||
| Completed |
NCT03283488 -
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
|
Phase 2 | |
| Recruiting |
NCT05503147 -
Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
|
Phase 1 |